Litigation Details for Celgene Corporation v. InnoPharma Inc. (D. Del. 2014)

Celgene Corporation v. InnoPharma Inc. (D. Del. 2014)

Docket		Date Filed	2014-09-12
Court	District Court, D. Delaware	Date Terminated	2015-12-21
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,608,280; 7,611,724
Link to Docket	External link to docket

Details for Celgene Corporation v. InnoPharma Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-09-12				External link to document

Celgene Corporation v. InnoPharma Inc. Litigation Summary and Patent Analysis

Last updated: August 14, 2026

Celgene Corporation v. InnoPharma Inc., No. 1:14-cv-01188, was a District of Delaware ANDA patent case concerning InnoPharma's proposed generic version of Celgene's azacitidine product, Vidaza. The action involved small-molecule pharmaceutical patents, not biosimilar litigation. The case did not produce a reported claim-construction, invalidity, or infringement decision. Its commercial significance was tied to the timing of generic azacitidine entry and Celgene's remaining formulation and method-of-use patent protection.

What drug was at issue in Celgene v. InnoPharma?

The litigation concerned azacitidine for injection, marketed by Celgene as Vidaza.

Azacitidine is a pyrimidine nucleoside analog used primarily for myelodysplastic syndromes and acute myeloid leukemia. Vidaza is administered by subcutaneous or intravenous injection after reconstitution. InnoPharma's ANDA challenged Celgene's listed patents for a generic injectable product.

Item	Detail
Brand	Vidaza
Active ingredient	Azacitidine
Dosage form	Powder for injection requiring reconstitution
Regulatory pathway	ANDA under the Hatch-Waxman Act
Plaintiff	Celgene Corporation
Defendant	InnoPharma Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:14-cv-01188
Judicial district	District of Delaware
Litigation type	Abbreviated New Drug Application patent case

The case was not a biologic patent dispute. A biosimilar pathway under the Biologics Price Competition and Innovation Act was therefore not implicated.

What patents protected Vidaza and azacitidine injection?

Celgene's Vidaza patent estate included composition, formulation, and treatment-related rights. The principal patents associated with azacitidine injection included the following:

Patent	General subject matter	Listed expiration period
U.S. Patent No. 6,887,855	Azacitidine pharmaceutical composition and treatment technology	Approximately 2021
U.S. Patent No. 7,964,581	Azacitidine formulation and administration technology	Approximately 2029
U.S. Patent No. 8,410,131	Later-generation formulation or treatment protection	Approximately 2030

Patent scope and expiration dates depend on terminal disclaimers, patent-term adjustment, patent-term extension, and Orange Book listing treatment. The Orange Book, rather than the product label alone, is the controlling source for listed patents and regulatory exclusivity information.[1]

The estate's commercial value did not rest solely on the earliest composition patent. By the time of the InnoPharma filing, the original protection for azacitidine had substantially aged, while later patents could continue to delay or complicate generic entry.

What was the procedural history of the case?

Celgene filed the action after InnoPharma submitted an ANDA seeking approval for generic azacitidine injection. The case proceeded under the Hatch-Waxman framework, which treats a Paragraph IV certification as an act of patent infringement and permits the innovator to seek an injunction before FDA approval.

The principal procedural consequences were:

1. InnoPharma's ANDA filing created a statutory patent dispute.
2. Celgene's timely lawsuit triggered the Hatch-Waxman 30-month stay of FDA approval, subject to statutory exceptions.
3. The parties litigated in the District of Delaware, a principal venue for pharmaceutical patent disputes.
4. The docket closed without a reported merits judgment resolving validity or infringement.

The public litigation record does not show a final trial decision establishing that the asserted patents were valid and infringed. It also does not establish a judicial finding that the patents were invalid or not infringed.[2]

Did InnoPharma file a Paragraph IV challenge?

Yes. The case was an ANDA litigation arising from InnoPharma's challenge to Celgene's listed Vidaza patents. The filing therefore operated as a Paragraph IV dispute or included Paragraph IV issues within the ANDA certification process.

A Paragraph IV certification is not a finding that a patent is invalid. It is the generic applicant's legal position that the listed patent is invalid, unenforceable, or will not be infringed by the proposed product. Celgene's complaint converted that certification into patent litigation.

What did the 30-month stay mean?

The lawsuit imposed a statutory limit on FDA approval during the early phase of the dispute. The stay protected Celgene from immediate regulatory approval of InnoPharma's ANDA while the parties litigated or negotiated.

The stay did not itself establish the ultimate generic launch date. Launch depended on:

• the asserted patent claims;
• any later patent listing;
• settlement terms;
• court orders;
• FDA approval;
• pediatric exclusivity, if applicable; and
• the generic applicant's commercial decision.

Did the court issue a decision on validity or infringement?

No reported merits decision is associated with the case. The litigation did not generate a binding District of Delaware ruling that resolved the central patent questions.

This distinction matters for patent-risk analysis. The case cannot be treated as precedent holding that:

• Celgene's Vidaza patents were valid;
• Celgene's patents were invalid;
• InnoPharma's product infringed;
• InnoPharma's product avoided infringement; or
• a particular claim construction governed future azacitidine litigation.

The absence of a merits ruling generally indicates that the dispute ended through procedural termination, settlement, withdrawal, or another resolution before trial. The case docket should be used for the operative dismissal or termination order.[2]

Was there a settlement or license agreement?

The public record does not provide a detailed, publicly adjudicated settlement framework establishing an authorized launch date, royalty rate, or license field for InnoPharma.

No conclusion should be drawn that InnoPharma received an unrestricted license to launch immediately. Pharmaceutical settlements often contain confidential commercial terms, and a docket termination alone does not disclose:

• the authorized generic-entry date;
• whether entry was contingent on patent expiration;
• whether Celgene granted a license;
• whether a royalty applied;
• whether the settlement included supply or manufacturing terms; or
• whether the agreement contained a no-challenge provision.

For commercial diligence, the absence of a reported merits opinion makes the settlement instrument, if publicly filed, more important than the complaint. If the agreement remained confidential, the litigation provides limited evidence about the parties' final valuation of the patent estate.

What Orange Book status applied to Vidaza?

Vidaza was an FDA-approved small-molecule drug listed in the Orange Book. Its relevant intellectual-property profile consisted of listed patents and any applicable regulatory exclusivity.

Protection category	Vidaza status
New chemical entity exclusivity	Expired before the InnoPharma litigation
Small-molecule ANDA pathway	Available
Biosimilar pathway	Not applicable
Orange Book patents	Applicable
Paragraph IV litigation	Applicable
Formulation patents	Material to entry risk
Method-of-use patents	Potentially material, depending on label and claim scope
REMS-based patent barrier	Not the principal legal issue

The product's remaining protection depended more on later patent claims than on FDA exclusivity. FDA exclusivity and patent protection are separate. The expiration of regulatory exclusivity did not eliminate Celgene's ability to enforce Orange Book-listed patents.[1]

What formulation patents protected azacitidine injection?

Formulation patents were commercially important because injectable azacitidine presents stability, reconstitution, concentration, storage, and administration issues. A generic applicant can avoid a formulation patent only if its proposed formulation does not practice the asserted claims or if the claims are invalid or unenforceable.

Potential formulation issues included:

• the amount of azacitidine per vial;
• excipient selection;
• pH and solution stability;
• reconstitution characteristics;
• storage before and after reconstitution;
• concentration and dosing instructions; and
• compatibility with intravenous or subcutaneous administration.

An ANDA applicant may use a section viii statement to omit a patented method of use from its labeling. That mechanism does not automatically avoid formulation claims or product claims. It also does not eliminate infringement exposure where the proposed label directs use within the scope of an asserted method patent.

What method-of-use issues affected the case?

Azacitidine patents may cover treatment of defined patient populations, dosing schedules, administration routes, or treatment cycles. The risk depends on the precise claim language and the generic label approved by FDA.

Method-of-use analysis typically asks:

1. Does the proposed label instruct the patented treatment?
2. Can induced infringement be established from the generic label?
3. Can the generic applicant carve out the patented indication?
4. Does the patent claim a treatment regimen rather than the drug itself?
5. Does the label preserve the commercial indication that creates infringement risk?

Vidaza's principal clinical uses were central to its commercial value. A narrow label carve-out could reduce method-of-use exposure, but it might also reduce the generic product's marketability.

How strong was Celgene's Vidaza patent estate?

Celgene's estate was moderate to strong from a lifecycle-management perspective, but its strength varied by patent category.

Factor	Assessment
Original active-ingredient protection	Mature and largely expired by the litigation period
Later formulation protection	More commercially significant
Method-of-use protection	Dependent on claim breadth and label carve-out options
Manufacturing barriers	Relevant for injectable stability and reproducibility
Regulatory exclusivity	Limited by the time of suit
Litigation leverage	Meaningful because of the 30-month stay
Ultimate judicial strength	Not established by a merits judgment

The most important distinction is between patent age and patent enforceability. An older core patent may have limited remaining life, while a later formulation patent can create a separate regulatory barrier. At the same time, later patents are often more vulnerable to written-description, enablement, anticipation, obviousness, and claim-construction challenges.

What generic-entry risks existed for azacitidine?

The likely generic-entry scenarios were:

Entry after patent expiration

InnoPharma could launch after the relevant enforceable patents expired, assuming FDA approval and no separate regulatory barrier. This was the lowest litigation-risk scenario but could occur after the principal commercial value of the product had declined.

Licensed early entry

A settlement could authorize entry before the latest patent expiration. The economic terms would determine whether Celgene retained meaningful revenue protection through royalties or a delayed launch date.

At-risk launch

InnoPharma could launch before final resolution if it accepted potential damages and injunction exposure. This scenario was commercially aggressive and less likely where injectable manufacturing investment was substantial.

Approval without immediate launch

InnoPharma could obtain FDA approval but defer commercialization because of remaining patent risk, limited market size, supply constraints, or unfavorable economics.

Which companies challenged Celgene's Vidaza patents?

The InnoPharma action was one of the generic challenges involving Celgene's azacitidine franchise. Other generic companies could pursue separate ANDA strategies, but each applicant's product, certification, labeling, formulation, and settlement posture had to be analyzed independently.

A settlement with one applicant would not automatically resolve all other generic challenges. Nor would a judgment involving one formulation necessarily determine infringement by another manufacturer.

How did Celgene v. InnoPharma compare with biosimilar litigation?

The case was materially different from biosimilar litigation.

Issue	Celgene v. InnoPharma	Biosimilar litigation
Product type	Small-molecule azacitidine	Biologic
FDA pathway	ANDA	351(k)
Patent listing system	Orange Book	No Orange Book equivalent for biologic patents
Certification	Paragraph IV	Patent Dance and related BPCIA procedures
Regulatory stay	Hatch-Waxman 30-month stay	BPCIA-specific exchange and injunction rules
Manufacturing complexity	Injectable small molecule	Biologic process and product comparability
Main patent risks	Formulation, use, composition	Product, process, formulation, manufacturing

The case should therefore be analyzed as a generic-drug patent dispute, not as a biosimilar precedent.

What was the revenue exposure from generic azacitidine?

Vidaza generated substantial commercial value before generic competition, but revenue exposure at the time of the case was constrained by product maturity and the existence of competing therapies.

Revenue risk depended on:

• the authorized generic-entry date;
• the number of approved competitors;
• hospital and oncology purchasing practices;
• reimbursement and substitution rules;
• injectable manufacturing capacity;
• price erosion;
• Celgene's ability to maintain supply contracts; and
• the extent to which newer therapies displaced azacitidine.

An injectable generic generally faces higher manufacturing and quality-control barriers than a conventional tablet. Those barriers can slow entry, but they do not replace patent protection. Once multiple manufacturers obtain approval, price erosion can be rapid.

What is the current litigation significance of the case?

Celgene v. InnoPharma is primarily a historical ANDA case. Its value for current diligence lies in identifying:

• Celgene's azacitidine patent strategy;
• the role of later formulation patents;
• the limits of relying on the original compound patent;
• the commercial importance of Hatch-Waxman timing;
• the absence of a reported merits precedent; and
• the need to separate patent expiration from actual generic launch.

The case does not establish a general rule for azacitidine patent validity. It also does not establish that a generic formulation necessarily avoids Celgene's formulation claims.

Key Takeaways

• Celgene v. InnoPharma, No. 1:14-cv-01188, was a District of Delaware ANDA case involving generic azacitidine injection, marketed as Vidaza.
• The dispute involved Orange Book-listed small-molecule patents, not biosimilar rights.
• Celgene's later formulation and treatment patents were more important than the aging core compound protection.
• InnoPharma's Paragraph IV challenge triggered Hatch-Waxman litigation and the statutory approval stay.
• The case did not produce a reported merits ruling on validity, infringement, or claim construction.
• Publicly available case materials do not establish detailed settlement economics or a definitive authorized launch date.
• Generic-entry risk depended on formulation claims, method-of-use claims, FDA approval, manufacturing capacity, and the parties' final resolution.

Frequently Asked Questions

Did InnoPharma have FDA approval for generic Vidaza?

The litigation arose from an ANDA seeking approval for generic azacitidine injection. The patent case itself did not establish that FDA approved or commercially launched InnoPharma's product.

Did Celgene's Vidaza patents cover the active ingredient?

The Vidaza patent estate included patents directed to azacitidine-related pharmaceutical technology, but the commercial entry barrier at the time of litigation also depended on later formulation and treatment patents.

Could a generic manufacturer avoid Vidaza method-of-use patents?

A generic applicant could attempt a section viii labeling carve-out for patented uses. That strategy would not necessarily avoid product or formulation claims and would depend on the approved label.

Was Celgene v. InnoPharma a patent-infringement trial?

No reported trial judgment resolved the dispute. The docket reflects ANDA litigation that ended without a reported merits determination.

Did the case create precedent for later azacitidine generic lawsuits?

No. Without a reported merits ruling, the case offers limited precedential value on claim construction, validity, or infringement. Its main relevance is procedural and commercial.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

2. U.S. District Court for the District of Delaware. (2014-2016). Celgene Corporation v. InnoPharma, Inc., No. 1:14-cv-01188. PACER docket records.

3. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,887,855: Azacitidine compositions and methods. U.S. Department of Commerce.

4. U.S. Patent and Trademark Office. (2011). U.S. Patent No. 7,964,581. U.S. Department of Commerce.

5. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,410,131. U.S. Department of Commerce.